KNSA Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals to Report First Quarter 2026 Financial Results on April 28, 2026

Kiniksa Pharmaceuticals to Report First Quarter 2026 Financial Results on April 28, 2026

LONDON, April 23, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 28, 2026 at 8:30 a.m. Eastern Time to report its first quarter 2026 financial results and recent portfolio execution.

A live webcast will be accessible through the Investors & Media section of the company’s website at . Individuals interested in participating in the call via telephone may register . Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.

About Kiniksa

Kiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksa’s portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. For more information, please visit .

Every Second Counts! ®

Kiniksa Investor & Media Contact

Jonathan Kirshenbaum

(781) 829-3949



EN
23/04/2026

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Kiniksa Pharmaceuticals

 PRESS RELEASE

Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results a...

Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution – ARCALYST® (rilonacept) Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth –– ARCALYST 2026 expected net product revenue increased to $930 - $945 million –– KPL-387 Phase 2 recurrent pericarditis data expected in 2H 2026; Phase 3 pivotal trial expected to initiate by year-end –– Q1 2026 cash balance increased to $468.1 million – – Conference call and webcast scheduled for 8:30 am ET today – LONDON, April 28, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: KNSA) (Kini...

David Nierengarten ... (+3)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
 PRESS RELEASE

Kiniksa Pharmaceuticals to Report First Quarter 2026 Financial Results...

Kiniksa Pharmaceuticals to Report First Quarter 2026 Financial Results on April 28, 2026 LONDON, April 23, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 28, 2026 at 8:30 a.m. Eastern Time to report its first quarter 2026 financial results and recent portfolio execution. A live webcast will be accessible through the Investors & Media section of the company’s website at . Individuals interested in participating in the call via telephone may register . Upon registration, all telephone participants will recei...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch